Carlsmed Sees Record Q4 2025 Revenue, Emphasizes Cost Cuts and Pipeline
Carlsmed recorded record Q4 2025 revenue, driven by adoption of its minimally invasive spinal implant system, and improved operating leverage through targeted cost reductions. Management confirmed full-year 2026 guidance and highlighted regulatory submission for its next-generation device with expected FDA clearance in late 2026.
1. Record Q4 Revenue Growth
Carlsmed achieved its highest quarterly sales in Q4 2025, led by strong uptake of its minimally invasive spinal implant system across key U.S. hospitals. The company noted double-digit year-over-year growth compared with the prior quarter’s performance.
2. Cost Controls and Cash Position
Management detailed completion of a targeted cost-reduction initiative that lowered operating expenses by over 10%, boosting operating leverage. These measures extended the company’s cash runway into late 2027, providing flexibility for R&D investment.
3. Pipeline and Regulatory Updates
During the call, Carlsmed announced submission of its next-generation spinal device to FDA with pivotal clinical data on track for mid-2026. Management expects regulatory clearance in late 2026, which could unlock broader market access and drive future revenue expansion.